Aurora Cannabis Inc. (ACB) Fair Value 2026

ACB · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.0 /10

32 fundamental signals · 11 models active

Value Trap Risk

LOW (30/100)

Quick Summary — As of 2026-07-15, Aurora Cannabis Inc. (ACB) trades at $2.66, approximately 178% above CirclFi’s Bayesian DCF fair value of $0.96. QOC: 5.0/10. Value Trap Risk: 30/100 (LOW). 11/13 models active.

Key Facts

Ticker
ACB
Price
$2.66
Quality Score
5.0/10
Value Trap Risk
30/100
Models Active
11/13
Last Updated
Strength: CUCE Ensemble suggests +81.0% upside with 2% confidence
Risk: Limited model coverage (11/13) may reduce confidence

Is Aurora Cannabis Inc. (ACB) Undervalued or Overvalued in 2026?

According to CirclFi’s 11-model valuation engine, Aurora Cannabis Inc. (ACB) appears undervalued as of : the median of 11 independent fair value estimates is $4.09, 53.9% above the current price of $2.66. Estimates range from $0.69 to $7.47. ACB scores 5.0/10 on fundamental quality and 30/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Aurora Cannabis Inc. Stock in 2026? →

Valuation Matrix

11 Intrinsic Value Models vs. Current Price ($2.66)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $0.96 -64.1%
Earnings Power Value
Low Conviction
 $4.09 +53.9%
CUCE Ensemble
Low Conviction
 $4.81 +81.0%
ML-RIV
Medium Conviction
 $0.69 -74.2%

Unlock the Full Matrix

Access 7 additional models including EROIC Spread, Dynamic NAV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 11 Models →

Cancel anytime · No contracts · Instant access

What Is Aurora Cannabis Inc. (ACB) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, our multi-model framework produces a cautiously optimistic read on Aurora Cannabis Inc. at $2.66. With an estimated intrinsic value of $3.94 and 7 of 11 models pointing higher, the average implied return is +48.1%. The most optimistic model, Regime Cross, places fair value at $7.47 (+180.7%), while ML-RIV — the most conservative — estimates $0.69 (-74.2%). This +254.8% gap reflects genuine analytical uncertainty about Aurora Cannabis Inc.'s intrinsic worth.

What Do the Models Say About ACB?

11 of 13 models are currently active for ACB. Of these, 8 models suggest upside while 3 models suggest overvaluation. The Bayesian DCF estimates ACB's intrinsic value at $0.96, implying -64.1% downside from the current price. See which stocks rank higher →

How Does ACB Rank in Drug Manufacturers - Specialty & Generic?

Among 13 Drug Manufacturers - Specialty & Generic stocks, ACB ranks #10 by Quality of Company score. CirclFi's QOC score of 5.0/10 evaluates 32 fundamental signals. A score of 5.0 reflects mixed fundamentals.

The Drug Manufacturers - Specialty & Generic sector introduces analytical considerations specific to pharmaceutical industry businesses. For Aurora Cannabis Inc., metrics like patent cliff exposure provide important context that general-purpose valuation models may underweight.

Is ACB a Value Trap?

CirclFi's Value Trap algorithm assigns ACB a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

11 of 13 models are active for Aurora Cannabis Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Aurora Cannabis Inc. earns a quality score of 5.0/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +254.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ACB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ACB's 11 active models, average confidence is 21%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Aurora Cannabis Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

8 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

AMPHAmphastar Pharmaceuticals, Inc.QOC 10.0ALKSAlkermes plcQOC 8.4AMRXAmneal Pharmaceuticals, Inc.QOC 8.0ANIPANI Pharmaceuticals, Inc.QOC 7.5AQSTAquestive Therapeutics, Inc.QOC 6.8ANIKAnika Therapeutics Inc.QOC 6.6ADCTADC Therapeutics SAQOC 6.4AKBAAkebia Therapeutics, Inc.QOC 5.8

Read investment analysis: AMPH · ALKS · AMRX · ANIP · AQST

Frequently Asked Questions About Aurora Cannabis Inc.

What is Aurora Cannabis Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Aurora Cannabis Inc. (ACB) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.96. The Quality of Company score is 5.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ACB overvalued or undervalued right now?

At $2.66, 8 of 11 active models suggest ACB may be undervalued, while 3 indicate potential overvaluation. The median of all 11 fair value estimates is $4.09, 53.9% above the current price of $2.66 — a consensus view that ACB is undervalued. The assessment depends on which methodology best fits Aurora Cannabis Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 5.0 mean for ACB?

Aurora Cannabis Inc.'s QOC of 5.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on ACB?

CirclFi analyzes ACB with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 11 of 13 are active for this stock. Read the full methodology →

Is ACB a value trap in 2026?

Aurora Cannabis Inc.'s Value Trap score is 30/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 11-model valuation engine, Aurora Cannabis Inc. (ACB) has a median fair value of $4.09 — 53.9% above the current price of $2.66 — as of 2026-07-15.” Source: circlfi.com/stock/ACB/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 11 mathematical frameworks give you clarity on ACB.

Unlock All 11 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access